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Abstract
Background: The hallmark of HIV-1 pathogenesis is the progressive CD4
+ T cell depletion and high propensity of CD4
+ T
cells to apoptosis. HIV-1 viral protein R (Vpr) is a major pro-apoptotic gene product. A first Vpr-mediated apoptotic
mechanism that requires a physical interaction of HIV-1 Vpr71-82 mitochondriotoxic domain containing the conserved
sequence 71-HFRIGCRHSRIG-82 with the Adenine Nucleotide Translocator (ANT) has been characterized. The family of Ser/Thr
protein phosphatase PP2A interacts with several viral proteins to regulate cell growth and apoptotic pathways. Previous
studies based on yeast two hybrid assays and mutational experiments indicated that PP2A1 is involved in the induction of
G2 arrest by HIV-1 Vpr.
Principal Findings: Experiments combining pull-down, cell penetration and apoptosis analyses in distinct human cells
indicate that the PP2A1 binding sequence from Vpr77–92 is a new cell penetrating apoptotic sequence. We also found that
the I84P mutation or the IIQ/VTR83–85 and T89A substitutions in the Vpr77–92 sequence prevent PP2A1 binding, cell
penetration and apoptosis. In addition the double R77A and R80A mutation known to inactivate the mitochondriotoxic
Vpr71–82 domain, has no effect on the biological properties of the Vpr77–92 domain.
Conclusion: Together our data provide evidence for the first time that the Vpr77–92 sequence delineates a biological active
domain of Vpr with PP2A1 binding and pro-apopototic capacities and, it is conceivable that this cell penetrating sequence
may account for the Vpr internalization in uninfected cells. Finally, our data also implicate the existence of two partially
overlapping pro-apoptotic domains in the Vpr C-terminal part, a redundancy that represents a new approach to address the
question of biological relevance of HIV-1 Vpr. In this context, future studies will be required to determine the functional
relevance of the Vpr77–92 domain in full length Vpr protein and also in entire HIV provirus.
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Introduction
HIV infection leads to the depletion of CD4+ T cells in patients.
The CD4+ T cells depletion of non-infected CD4+ T cells has been
correlated to an increased propensity to apoptosis, which relays on
induced host and viral factors [1]. HIV-1 Viral Protein R (Vpr) is
one of the regulatory HIV-1 proteins that are important for in vivo
establishment and/or maintenance of AIDS pathogenesis. Multiple
studies indicate that Vpr regulates viral replication in vivo and is
required for virus replication in non-dividing cells. In addition, Vpr
induces cell cycle arrest in proliferating cells, stimulates virus
transcription and can induce apoptosis of infected cells [2].
Previous studies also suggested that Vpr can induce apoptosis in
distinct human cells as a consequence of the prolonged cell cycle arrest
[3,4]. Other reports have clearly documented a major apoptotic
mechanism which is based on the physical interaction of Vpr with the
Adenine Nucleotide Translocator (ANT), a component of the
permeability transition pore of mitochondria localized in the inner
mitochondrial membrane [5,6]. This mitochondriotoxic domain
contains Vpr71–82 sequence that is partially located at the end of the
third a-helix of Vpr (Vpr55–77). Vpr is actively secreted when it is
produced during the end part of the virus cycle and has been found in
biological fluids of patients. Interestingly it is capable of permeating
uninfected cells and may be responsible for bystander effect.
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13760The reversible phosphorylation of proteins controlled by protein
kinases and protein phosphatases is a major mechanism that
regulates a wide variety of cellular processes. Protein phosphatase
type 2A (PP2A) represents a major family of serine/threonine
protein phosphatases that has been implicated in the regulation of
many cellular events, including cell growth and apoptosis in
mammalian cells [7]. PP2A proteins comprise dimeric or
heterotrimeric enzymes. The dimeric PP2A core enzyme consists
of a catalytic C subunit (PP2Ac) and a structural A subunit. A third
subunit (B, B’, B’’ or B’’ ’) can eventually bind to the core and
regulate both the substratespecificityandlocalization ofthetrimeric
holoenzyme. PP2A1 is a trimeric form composed of A, Ba and C
subunit [8]. To specifically compete with the binding of regulatory
subunits to PP2A core or to PP1 catalytic subunit, we previously
described a novel approach named Drug Phosphatase Technology
(DPT). This approach is based on the use of penetrating peptide
sequences that interact with PP1/PP2A holoenzymes to specifically
disrupt or modulate apoptotic pathways [9].
In this study, we first identify 89.6-Vpr77–92 sequence as a PP2A1
binding domain. In addition we showed that IIQ/VTR83–85 and
T89A substitutions in the pNL4.3-Vpr77–92 sequence, inhibits PP2A1
binding and apoptosis. These results suggest that PP2A1-binding site
of Vpr77–92 C-terminal sequences control the cell penetrating death
activities of this new functional domain. Altogether, these data allow
us to define DPT-Vpr1, a new cell penetrating death molecule,
derived from the sequence of 89.6-Vpr77–92.
Results
Vpr72–92 is a PP2A1 binding sequence
Since previous experiments have indicated that the cell PP2A1
holoenzyme is involved in the mode of action of Vpr, we explored
whether Vpr and PP2A1 could establish physical interaction by
performing affinity chromatography. Recombinant full length
Vpr-T protein encoded by the HIV-1 (89.6 isolate) was coupled
with column agarose beads and purified PP2A1 holoenzyme was
chromatographied on the column. Phosphorylase a phosphatase
activity was found exclusively in the fractions eluted by salinity
gradient and picking at 0.3M NaCl (Fig. 1A). In addition, the
phosphatase activity from both eluted Vpr-Agarose column and
from purified PP2A1, display a similar sensitivity to protamine
stimulation indicating the conservation of PP2A1 subunit compo-
sition and enzymatic properties after Vpr-agarose binding (Fig.S1).
Furtheremore, to identify Vpr sequences able to bind in vitro to
PP2A1, a series of 43 overlapping dodecapeptides from 89.6-Vpr
were synthesized onto a cellulose membrane. The membrane was
incubated with purified PP2A1 holoenzyme or with isolated PP2A1
subunits. Three overlapping peptides corresponding to a docking
site, named site 1, that binds to trimeric PP2A1 holoenzyme were
detected (Fig. 1B). Similarly two overlapping peptides correspond-
ing to the same PP2A1 docking site 1 were also detected when the
membrane was incubated with the structural PP2A-A subunit
(Fig. 1B). In addition, we also detected four overlapping peptides
that define a second putative binding site, named site 2, for PP2A-
A subunit. In contrast, no interactive spot was detected with
purified PP2A-Ba and PP2Ac subunits (data not shown). These
data allowed to identify RHSRIGIIQQRRTRNG (Fig.1C) as a
new Vpr sequence that binds in vitro to the PP2A1 holoenzyme
through its structural PP2A-A subunit.
The 89.6-Vpr77–92 peptide sequence interacts with PP2A1
in cell extracts
We further characterized the capacity of Vpr77–92 domain to
bind PP2A1. By using streptavidine magnetic beads, we attempted
the PP2A1 co-precipitation following incubation of extracts from a
variety of cell lines with biotinylated peptides relaying to the
Vpr77–92 the docking site 1 sequence. The sequence alignments of
Vpr proteins and the different peptides tested are respectively
listed in Table 1 and Table 2. Both DPT-Vpr1 and DPT-Vpr3,
that respectively correspond to the wild type and a mutated Vpr77–
92 sequence of 89.6 viral isolate, pulled down PP2A1 in cell
extracts. DPT-Vpr3 varied from DPT-Vpr1 by the replacement of
three residues by a residue A at the positions R72, R75 and T89.
In contrast the IIQ/VTR83–85 substitutions or the single residue
replacement (I84P) corresponding to DPT-Vpr2 and Vpr4
peptides respectively prevented detection of any PP2A1 subunit
in the pull down samples (Fig. 1D, Fig. S2 and Fig. S3, and data
not shown). Taken together the pull down experiments account for
the specific binding of DPT-Vpr1 peptide to PP2A1. Our results
also suggest, that in addition to the residue I84, the other residues
in vicinity (residues 83–85) play a critical role for the targeting the
PP2A1-binding domain. Future genetic analyses will be required to
adress their contribution.
The Vpr77–92 sequence from HIV-1 89.6 strain is a new cell
penetrating domain
It is well established that Tat peptides derived from the cell
penetrating protein HIV-1 Tat are cell penetrating sequences that
allow intracellular delivery of proteins. Tat transduction depends
on various factors, and current protocols permit the transduction
into many cells [10]. Since Vpr is a known as cell penetrating
protein, we hypothesized that DPT-Vpr peptides containing the
Vpr77–92 sequence could also display a transduction activity. To
test whether DPT-Vpr peptides display similar activity, biotiny-
lated DPT-Vpr peptides were assessed to penetrate and to deliver
a protein marker (Streptavidin-HRP) into HeLa cells. As shown in
figure 2A, Tat, DPT-Vpr1, DPT-Vpr2 and DPT-Vpr3 peptides
penetrate into HeLa cells. However, Tat and DPT-Vpr peptides
showed subtle cell staining differences concerning their intra-
cellular localization. While Tat, DPT-Vpr1 and DPT-Vpr3 mostly
provided a homogeneous cytoplasm labeling, DPT-Vpr2 provided
also nuclear/nucleolar labeling. Then the capacity of the
biotinylated DPT-Vpr peptides to cargo protein into cell was
analyzed. The amounts of HRP internalized by incubating the
cells for five hours with three different biotinylated DPT-Vpr
Streptavidin-HRP complexes were shown in figure 2B. DPT-Vpr1
and DPT-Vpr3 peptides (50 mM) resulted in higher levels of HRP
internalization than Tat-peptide, the positive reference of the assay
(16.7 and 45.3 fold increase respectively). Although DPT-Vpr2,
was found able to permeate cells (Fig. 2A), surprisingly no cargo
effect could be detected with cells incubated with Streptavidin-
HRP linked to biotinylated-DPT-Vpr2, the signal recorded
remained as low as the cells control incubated with the media
plus Streptavidin-HRP alone. Thus the lack of cargo effect with
DPT-Vpr2 peptide correlated with its inability of binding to PP2A1
from cell extracts.
The Vpr77–92 sequence from HIV-1 89.6 strain is a new cell
death domain
Given the critical role of PP2A in the control of apoptotic events
and in consistence with the rational of our DPT concept, we
hypothesized that DPT-Vpr1 could contain a naturally occurring
pro-apoptotic DPT-sequence. To test this possibility, we first used
TUNEL assay to monitor apoptosis in adherent HeLa or neuronal
SK-N-SH cells. Figure 3A illustrates the high apoptotic level
obtained in SK-N-SH cells treated with DPT-Vpr1 and DPT-
Vpr3, in contrast, DPT-Vpr2 has no significant effect. This
PP2A Binding Domain in HIV-Vpr
PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e13760Figure 1. Analysis of HIV-1 Vpr and PP2A1 interaction. (A) 16 mg of PP2A1 holoenzyme purified from pig brain was loaded on a 1 mL HIV-1
strain 89.6-Vpr-T-agarose column equilibrated in buffer C (25 mM TrisHCl pH 7.4, 50 mM NaCl, 0.1 mM EDTA). The column was washed with 10 mL of
buffer C and then developed with a 18 mL linear gradient of buffer C to buffer C plus 1 M NaCl. Phosphatase activity of collected fractions was
assayed with phosphorylase a as substrat (1U =1 pm of phosphate liberated by 10 mL of fraction/min). A major peak of phosphatase activity was
detected, eluting at 0.3 M NaCl. (B) ECL revelation of PP2A binding assay on cellulose-bound Vpr peptides. 43 overlapping dodecapeptides with a
two-amino acid shift scanning the entire 89.6-Vpr sequence (accession number: AAA81039) were synthesized on a cellulose membrane. The
membrane was incubated with PP2A1 holoenzyme (upper panel) or PP2A-A subunit (lower panel) and subsequently with anti-PP2A antibodies
followed by peroxydase-labelled anti-guinea pig antibodies. (C) Sequence of HIV-1 Vpr protein: sequence of the two PP2A-A binding sites are
indicated in bold. These sequences correspond to overlapping sequences of positive dodecapeptides 29 to 32 (PP2A-A subunit incubation) or 39 to
41 (PP2A1 incubation). (D) Co-precipitation of DPT-Vpr peptides with PP2A1 in HeLa cell extracts. Control magnetic beads coupled with streptavidin
alone or conjugated with DPT-Vpr peptides at a concentration of 100 mM, were incubated with cells extracts (5.105 cells). Identification of bound
proteins in pull-down experiments was realized by immunoblotting using antibodies against PP2A1 subunits A, Ba and C.
doi:10.1371/journal.pone.0013760.g001
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and we found that DPT-Vpr1 and DPT-Vpr3 induce apoptosis in
60 to 75% of the cells (Fig. 3B). DPT-Vpr1 and DPT-Vpr3-
meditated apoptosis was also assayed in non-adherent Jurkat T
cells using Annexin V, an early marker of apoptosis. As indicated
in figure 4 upper panel, DPT-Vpr1 and DPT-Vpr3 peptides but
not DPT-Vpr2, induced phosphatidylserine translocation. Fur-
thermore we also analyzed a possible drop in mitochondrial
membrane potential (DYm), an earlier event in apoptosis. We
found that similarly to Vpr71–96, a control peptide containing the
mitochondrial death domain from pNL4.3 [11], DPT-Vpr1 and
DPT-Vpr3 but not DPT-Vpr2 induced a decrease in DYm (Fig. 4
lower panel). All together these results indicate that the Vpr77–92
sequence from 89.6 isolate is a new PP2A1-binding death domain.
Interestingly divergent residues with 89.6 Vpr77–92 sequence are
located in the Vpr77–92 domains from a previously published long-
term non progressive (LTNP) cohort [12].
Discussion
Vpr is a small basic protein that seems to be well conserved in
HIV-1, HIV-2 and SIV [13]. However the sequence of the non-
helical C-terminal portion, Vpr71–96, appears to be divergent in
HIV-2 and SIVmac and previous results indicate that HIV-1 Vpr
proteins contain a specific and highly conserved mitochondrial
death domain [14] (see table 3). In this work for the first time we
reported on biological activity of Vpr77–92, a short sequence
located on C-terminal part of Vpr delineated by the residues (77–
92). We demonstrated that this sequence is a second apoptotic
domain.
The Vpr77–92 sequence is a new multifunctional biological
domain with PP2A1-binding, cell penetrating and cell
death properties
Initial studies based on yeast two hybrid experiments suggested
that Vpr interacts with the structural PP2A-A subunit and can
induce cell cycle arrest [15,16]. Furthermore, the role of PP2A in
Vpr-induced G2 arrest was previously analyzed by pharmacolog-
ical and genetic analyses in yeast and in mammalian cells
[17,18,19,20,21]. Here, based on biochemical studies we have
found that the trimeric PP2A1 holoenzyme binds to full length Vpr
protein. Using peptide bound assays we clearly found that Vpr can
interact with the PP2A-A subunit. Furthermore, we determined
two distinct sequences, Vpr57–73 named site 2 and Vpr77–92 named
site 1, that interact with the structural PP2A-A subunit. However,
only site 1 is able to bind PP2A1 holoenzyme. This may suggest
that the A subunit of the trimeric PP2A1 holoenzyme could
contain a masked docking region for site 2 which appears to be
accessible on the isolated PP2A-A subunit. Furthermore since site
2 is located in the third helix of HIV-1 Vpr it is conceivable that
this kind of helical structure cannot interact with the trimeric
PP2A1 holoenzyme. Indeed, this position also corresponds to a
Leu/Ile-rich domain (amino acids 60–81), which is critical for
dimerization [22] and therefore this domain should be unable to
intracellularly interact with PP2A1. These observations clearly
suggest that site 2 represents a cryptic and possibly a non
functional PP2A-binding sequence. Furthermore PP2A1 binding
specificity of DPT-Vpr1, a peptide containing the site 1 sequence,
was substantiated by testing several peptides modified by residue
substitution. We found that the IIQ/VTR83–85 substitutions or the
single residue substitution I84P prevented the PP2A1 binding. In
contrast the double substitution, R77A and R80A, allowed the
binding to PP2A1 holoenzyme.
According to Drug Phosphatase-Technology concept PP2A
interacting sequences could represent new biologically active cell
penetrating peptides [9]. It is well establisehed that, similarly to
some cationic peptides, Tat peptide derived from the HIV-1 Tat
protein possessed protein transduction activity. Compared to the
activity of Tat peptide, DPT-Vpr1 has a more potent activity in
transporting streptavidin-HRP molecules. In contrast the DPT-
Vpr2 peptide that contains the IQQ/VTR83–85 and T89A
substitutions is unable to deliver streptavidin-HRP molecules
into HeLa cells. This result suggests that intracellular transduc-
tion is favored by the specific interaction with PP2A1 when
peptide is in the cell. A similar situation has been previously
observed using PP1, PP2A or PKA interacting sequences coupled
to inactive non-transducing shuttle DPT-sh1 [9,23]. Previous
studies showed that the C-terminal moiety of Vpr LAI strain
(containing the residues 52–96) possessed transducing activity in
human cell lines [24]. Vpr55–91 sequence containing our newly
identifiedPP2A1 bindingdomainis themostefficienttransducing
sequence. In addition, Taguchi et al., [25] identified a shorter
Table 1. Sequence alignment of Vpr proteins from two
different origins.
ORIGIN SEQUENCES
HELIX I HELIX II
11 02 03 04 05 0
89.6 MEQAPEDQGPQREPYNDWTLELLEELKNEAVRHFPRIW-
LHSLGQHIYETY
NL4.3 MEQAPEDQGPQREPYNEWTLELLEELKSEAVRHFPRIWL-
HNLGQHIYETY
60 70 80 90
HELIX III
89.6 GDTWTGVEALIRILQQLLFI HFRIGCRHSRIG IIQQRRTRNGASKS
NL4.3 GDTWTGVEALIRILQQLLFI HFRIGCRHSRIG VTRQRRARNGASRS
*** *
Single letter code for amino acids (aa) is used. The three a-helixes are Helix I, aa
17–33, Helix II, aa 38–50 and Helix III, aa 56–77. Variable sequence of the PP2A1
binding domain (77–92) is in red. Non variable sequence of mitochondrial death
domain is in italic (71–82). *Asterisks indicate distinct residues in 89.6-Vpr
(accession number: AAA81039) and VprpNL4.3 (accession number: AF324493)
that are located in PP2A1 binding domain. Mutational studies in yeast,
suggested that the T89A substitution in NL4.3-Vpr has no apoptotic effect [46].
The K95R substitution in 89.6-Vpr is outside of PP2A1-death domain.
doi:10.1371/journal.pone.0013760.t001
Table 2. Origin of peptides containing wild type and
mutated Vpr sequences derived from 89.6 and pNL4.3
sequences used in this study.
ORIGIN ACRONYM SEQUENCES
89.6 DPT-Vpr1 RHSRIGIIQQRRTRNG
NL4.3 DPT-Vpr2 RHSRIGVTRQRRARNG
89.6 DPT-Vpr3 AHSAIGIIQQRRARNG
89.6 DPT-Vpr4 RHSRIGIPQQRRTRNG
NL4.3 *Vpr71–96 HFRIGCRHSRIGVTRQRRARNGASRS
-Mutated residues in DPT-Vpr3/DPT-Vpr4 peptides containing Vpr77–92
sequences derived from 89.6 and divergent residues from pNL4.3 in DPT-Vpr3
and in *Vpr71–96 are in bold.
-*From Arunagiri et al.
11
doi:10.1371/journal.pone.0013760.t002
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sponding to the residues 52–78 of the third a-helix domain of
HIV-1 Vpr as a new cell penetrating sequence with transducing
activity. It is noteworthy that both Vpr55–91 and Vpr52–78
respectively contain the in vitro PP2A-A binding site 2 and the site
1 sequences identified in this study. In accordance with our
published DPT-concept, this observation highlights a potential
general role of PP2A in transducing efficiency. Further studies
will however be required to establish a possible biological
relevance of Vpr site 2 in PP2A-mediated transduction pathways.
Previous reports indicate that full length Vpr or peptides with
sequences derived from the C terminus Vpr proteins enter the
cell and cause death of human cells and yeast cells [5,11,26]. This
death effect requires the presence of a short C-terminal domain
containing the conserved mitochondrial death sequence
71-HFRIGCRHSRIG-82.
The Vpr77–92 domain : a new approach to decipher Vpr-
induced apoptosis in human cells
An area of studies has documented the capacity of Vpr to
induce apoptosis. Few intracellular Vpr targets that may direct
different mechanisms of apoptosis pathways have been identified.
Previous reports indicate that Vpr association with a Cul4A-
containig E3 ligase complex via its association with DCAF1
prevents ubiquitination and degradation of cellular protein
required for cell cycle progression [27]. The possibility that Vpr
association with this complex may be a causality link between cell
cycle control arrest and apoptosis occurrence has recently
garnered credit. Residues distantly spread on Vpr (Q3, Q65,
R77, R80) have been found to play some role in G2 cycle arrest
illustrating the fact that whole part of the protein is required for
active cell cycle arrest. Interestingly the R80A substitution renders
also Vpr inactive for cell cycle arrest but the R77A and R80A
Figure 2. Effect of DPT-Vpr peptides on cell penetration and intracellular delivery of streptavidin-peroxydase. (A) For penetration and
localization analysis, cells were incubated with 150 mM of peptides for 2 h at 37uC. After fixation, the presence of biotinynlated peptides is revealed
by incubation of permeabilized cells with streptavidin-peroxydase. The sequence of non penetrating peptide used as negative control is GVIFYLRDK.
The sequence of positive Tat control is YGRKKRRQRR. (B) Intracellular delivery of streptavidin-peroxydase by biotinylated-DPT-Vpr and Tat peptides in
HeLa cells. Streptavidin-peroxydase coupled with biotinylated peptides were incubated for 6 h at 37uC and internalized complexes were visualized by
a colorimetric test. Statistical analysis was carried out using Anova’s test and significance was assessed at p,0.0001.
doi:10.1371/journal.pone.0013760.g002
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inactivate the michondriontoxic domain activity did not prevented
apoptosis induction [28]. By testing these substitutions with DPT-
Vpr3 we did not find obvious impact on the pro apoptotic property
of our new Vpr77–92 domain suggesting that both ANT and PP2A
binding domains regulate Vpr-mediated apoptosis. Indeed ANT
and PP2A1 binding domains have a seemingly redundant ability to
direct an apoptosis process indicating that the Vpr71–92 sequence is
a new structural and functional domain.
It was previously published that the mutation R77Q of HIV-1
Vpr frequently occurs in HIV-1 infected Long Term Non
Progressor (LTNP) patients [12]. This mutation impairs the
molecular interaction of HIV-1 Vpr proteins with ANT resulting
in inactivation of the mitochondrial Vpr71–80 death domain [14].
However this is a controversial observation, more recently
challenged by studies reporting that the mutation R77Q can’t
be associated to reduce HIV-1 infectivity [29]. Interestingly, since
Vpr is also present in the body fluids of HIV-1 patients including
plasma and CSF [30,31], it is conceivable that both soluble full
length Vpr proteins and C-terminal processed fragments could
induce a bystander death effect in non-infected CD4+ cells. We
also can hypothesize that Vpr77–92 sequence from entire or C-
terminal processed protein sharing the penetrating properties of
89.6- Vpr77–92 sequence, should penetrate and provoke apoptosis
in both infected or non infected cells.
Neurocytopathic effects induced by a recombinant Vpr
molecule in neuronal cells suggest that Vpr is involved in the
genesis of neurological disorders [32,33,34,35]. In addition, it has
been shown that Vpr can be found in brain section of HAND
patients, specifically in astrocytes and neurons [36] and neuronal
cell death was observed in these patients, concomitantly with the
presence of Vpr protein and transcripts [37]. Furthermore, in
contrast to peptides containing the mitochondriotoxic sequence
(residues 71–82), the peptidic sequences spanning the C-terminal
domain of Vpr (residues 52–96 or 70–96) induced apoptosis in
cultured rat cortical and striatal neurons [38]. These data imply
Figure 3. Effect of DPT-Vpr peptides on cell death. (A) Nuclear morphology illustrated with SK-N-SH cells was evaluated with DAPI (blue) and
DNA strand breaks were identified using TUNEL labeling (green). (B) Histograms show percentages of positive SK-N-SH cells (left panel) or HeLa cells
(right panel) detected in TUNEL assay.
doi:10.1371/journal.pone.0013760.g003
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to induce apoptotic pathway in neurons [38,39]. Interestingly, our
cell death experiments in neuron derived SK-N-SH cells indicate
that DPT-Vpr1 is also potently active in neuronal cells. In
consistence with the existence of soluble forms of Vpr in biological
fluids, our results likely suggest a biological effect of our new
biologically active Vpr77–92 domains in Vpr-mediated neurode-
generation.
In conclusion, our identification of a new biological domain has
multiple consequences for development of future researches in
HIV-1 field. First it is a priority to study whether or not the
Vpr77–92 domain is biologically active in the context of the full
length Vpr protein and of HIV replication. Interestingly, the
complex structural organization of the vpr gene with two
overlapping pro-apoptotic sequences raises several questions about
its biological relevance. We can speculate that such gene
organization should increase genomic information to counteract
the HIV genomic variation occurrence. In addition the existence
of overlapping ANT and PP2A1 binding sequences may lead to
eventual binding competition between the two ANT and PP2A1
pro-apoptotic cell targets. Because Vpr is prone to be interacting
with an area of cells, such as infected resting and/or activated cells
and non-infected cells, it is conceivable that either pathway may
concern preferentially alternate cell phenotypes.
In addition our results suggest the hypothesis that non active
sequences of the new PP2A1-dependant Vpr77–92 death domain
could be implicated as a regulator of long-term non-progression as
well as a viral pathogenicity factor. Especially, functionally active
PP2A1 binding Vpr77–92 death sequences in HIV-1 isolates should
be a positive event for AIDS progression and potential
development of HIV Associated Dementia (HAD). Focusing on
the case of HAD, since some ART treatments don’t cross the
blood-brain barrier [36,37], it will be important to identify new
DPT-peptides or/and to design new chemical drugs that compete
with Vpr77–92 PP2A1 binding sequence. Such synthetic blockers of
the Vpr77–92 domain/PP2A1 interaction will obviously have an
impact on the HIV-1 pathogenesis. More generally, the use of new
DPT-peptides targeting PP2A1 will be useful to study different
neurodegenerative diseases such as Tauopathies in which PP2A1
plays an important role [40]. These molecules should have a more
specific action than currently available drugs.
Materials and Methods
Kits and Reagents
An 8 well Lab-Tek II Chamber Slide, Nalge Nunc Interna-
tional), streptavidin Horse Radish Peroxidase conjugate (Euro-
medex,), 3,39-diaminobenzydine tetrahydrochloride (DAB) of
DAB Substrate Kit for Peroxidase (Vector laboratories), ‘‘complete
mini EDTA free’’ protease inhibitor cocktail from Roche, O-
Phenylenediamine-dihydrochloride (OPD) tablet from Sigma
chemical, Annexin-V-FITC from Roche, DiOC6(3) from Sigma,
Kit DeadEnd
TM Fluorometric TUNEL system product (Promega),
FluorSave
TM Reagent from Calbiochem, Vectashield mounting
medium for fluorescence, with DAPI (Vector Laboratories),
Trypsin EDTA, Invitrogen.
Cell Culture and Reagents
Adherent HeLa cells (American Type Culture Collection
(ATCC): CCL-2, Manassas, VA) were cultured in Dulbecco’s
modified Eagle’s medium (D-MEM, Invitrogen) as exponentially
growing sub confluent monolayers in micro plates or in 12-, 24- or
96- well plates. Jurkat lymphoid T cells (clone E6, ATCC: TIB-
152) were cultured in RPMI 1640 Glutamax Medium (Gibco;
Invitrogen). Both cell lines were cultured in medium supplemented
with 10% fetal calf serum (Invitrogen). Adherent SK-N-SH cells
(neuroblastoma cells, ATCC: HTB-11) were cultured in DMEM
Glutamax-I-High Glucose (Gibco) with 10% fetal calf serum
(Gibco/BRL).
Peptides
High-performance liquid chromatography-purified NH2–bioti-
nylated peptides (purchassed from Neosystem) were prepared by
solid-phase peptide synthesis. Peptides were dissolved in DMSO
and stored at 4uC until use or in half of EtOH and 150 mM NaCl
and stored at 220uC pending use.
Vpr, PP2A proteins and antibodies
Full length HIV-1 89.6-Vpr was prepared in a 6-his C-term
tagged form (Vpr-T) by expression in bacteria as described
previously [41,42]. Vpr-T agarose column was generated by
binding Vpr-T onto a nickel charged iminodiacetic acid-
Sepharose-4B (Amersham Biosciences). Protocol for purification
of PP2A proteins: trimeric PP2A1 purification from pig brain was
adapted from methods previously described [43]. Preparation of
recombinant PP2A-A, PP2A-Ba and PP2A-C proteins as well
PP2A antibodies (polyclonal guinea pig anti-A, or anti-B and anti-
C subunits) has been previously described [44]. In western-blot
anti-Guinea Pig-HRP were used to 1/5000 (DAKO P0141).
In vitro phosphatase assay
32P-labeled phosphorylase a was prepared by phosphorylation
of phosphorylase b with phosphorylase kinase and the phosphor-
ylase phosphatase activity was assayed as described previously
[43].
PP2A-binding assays on cellulose-bound Vpr peptides
Overlapping dodecapeptides scanning the whole Vpr sequence
were prepared by automated spot synthesis (Abimed, Langerfeld,
Germany) onto an amino-derived cellulose membrane, as
described [45]. Membrane was blocked using SuperBlock (Pierce),
Table 3. Amino acid sequence alignement of Vpr proteins
from different origins in the vicinity of mitochondriotoxic and
PP2A-dependent death domains.
ORIGIN SEQUENCES
HIV-1 89.6-Vpr 71-HFRIGC RHSRIG IIQQRRTRNG-92
HIV-1 LAI-Vpr ------ ------ ------A---
HIV-1 NL4.3-Vpr ------ ------ VTR---A---
HIV-2 GH1-Vpr -L-A-- NR---S QTRRR-PFP-
SIVmac-Vpr ---G- I----- QPGGGNPLSA
Vpr71–92 sequence from 89.6 isolate contains the two distinct overlapping
mitochondriotoxic Vpr71–82 and PP2A Vpr77–92 death domains. Non-identical
residues in HIV-1 (LAI and NL4.3), HIV-2 (GH1) and SIVmac are shown.
doi:10.1371/journal.pone.0013760.t003
Figure 4. To monitor apoptosis in Jurkat cells treated with DPT-Vpr peptides, we used Annexin V (upper panel) or DiOC6 (lower
panel) assays. For DiOC6 statistical analysis was by Anova and significance was set at p,0.05.
doi:10.1371/journal.pone.0013760.g004
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PP2A1 holoenzyme and after several washing steps, incubated with
anti-PP2A antibodies, followed by PO-conjugated secondary
antibody. Positive spots corresponding to PP2A-binding peptides
were visualized using the ECL system.
Pull down assays to detect interaction of biotinylated
peptides with PP2A1 target
Biotinylated peptides were pre-incubated 2 h at 100 mMo r
200 mM (in final concentration with lysate) at room temperature
with 30 ml of streptavidin-coated immunomagnetic beads (Calbio-
chem, San Diego CA). During this time, 1610
6 HeLa cells at 90%
of confluence per peptide point assay were trypsinized, washed
with 1 mL of phosphate-buffered saline (PBS), and centrifuged at
600 g and 4uC for 10 min. Cell pellets were lysed 10 min on ice
with 400 ml of lysis buffer (50 mM Tris pH 7.4, 200 mM NaCl,
10 mM EDTA, 20% Glycerol, 1% Nonidet P-40, 1 mM
phenylmethylsulfonyl fluoride (PMSF), 10 mM NaF, 1 mM
orthovanadate, and ‘‘complete mini EDTA free’’ protease
inhibitor cocktail from Roche). Lysates were clarified at 13,000 g
for 10 min at 4uC and after rotation with supernatant at 4uC for
2 h biotinylated peptides were pulled down with streptavidin
magnetic beads and washed twice with 750 ml of lysis buffer.
Bound proteins and clarified lysates were analyzed by western
blotting using PP2A1 antibodies.
Cellular Localization of biotinylated Peptides
A total of 4610
4 exponentially proliferating HeLa cells growing
in a sub confluent monolayer were seeded per well on a Lab-Tek
and incubated at 37uC, 5% CO2. Biotinylated peptides were
added 48 h later to the cells at different concentrations for
different periods of time. Cells were washed twice in PBS, and
fixed with absolute ethanol for 10 min at –20uC before addition of
100 mM of streptavidin HRP conjugate After 30 min incubation at
37uC, cells were rinsed twice in PBS and incubated with DAB for
around 10 min. Cells were washed in distilled water and mounted
for microscopic examination.
Quantification of Peptide Internalization
Before incubation, the peptides were pre-incubated for 1 h with
streptavidin HRP conjugate in a 4:1 ratio. Cells at 80% confluence
were incubated with different concentrations of peptide in 24-well
plates. After 6 h, cells were washed twice in PBS, trypsinized and
harvested in 1 ml of PBS and counted. Cells were lysed in 300 ml
of 0.1 M Tris pH 7.4, and 0.5% Nonidet P-40 buffer for 10 min
on ice. A total of 50 ml of cell lysate was mixed with 50 ml of OPD
buffer (51.4 mM Na2HPO4 and 24.3 mM citric acid) then mixed
with 100 ml of OPD solution according to manufacturer’s
instructions. After 10 to 20 min, the reaction was stopped by
adding 100 ml of 1M HCl, and optical density was read at 490 nm.
TUNEL Assay
TUNEL assays were performed according to manufacturer’s
instructions. A total of 4610
4 HeLa or SK-N-SH cells were seeded
per well on a Lab-Tek II and incubated at 37uC, 5% CO2,
biotinylated peptides were added to the cells 18 h later at different
concentrations for different periods of time. Slides were rinsed
three times in PBS and mounted with Vectashield containing
DAPI. After that the slides were examined by fluorescence
microscopy.
Annexin-V assays and evaluation of mitochondrial
membrane potential (DYm)
Jurkat cells (2.5.10
5 cells in 400 mL of complete RPMI-1640
medium) were incubated at 37uC and 5% CO2 with different
peptide concentrations. After 3 h, cells were washed in PBS and
we used an Annexin-V-FITC to assess outer leaflet phosphatidyl-
serine (PS) exposure in the plasma membrane as a means for the
early detection of apoptotic cells. Staining was performed
according to the manufacturer’s instructions. We also used the
cationic Dye DiOC6(3), which localizes into intact mitochondria,
to measure DYm. DiOC6(3) was added at 20 nM for 15 to 30 min
at 37uC in the dark. Cells were washed in PBS and immediately
analyzed by flow cytometry. A total of 20,000 cells were analyzed
in a FACScalibur flow cytometer (BD Biosciences, San Jose, CA).
Supporting Information
Figure S1 Comparison of the effect of protamine on PP2A1 and
on the phosphatase eluted from HIV-1 Vpr-Agarose column.
Phosphorylase a phosphatase activities of purified PP2A1 and
from the pool of the 4 most active fractions eluted from HIV-1
Vpr-agarose column chromatography were assayed in the
presence of increasing concentration of protamine added without
pre-incubation. The activity in the absence of protamine was taken
as 100%.
Found at: doi:10.1371/journal.pone.0013760.s001 (6.02 MB TIF)
Figure S2 Effect of DPT-Vpr4 peptide on PP2A-interaction, cell
penetration, and cell death. (A) Cell penetration was analyzed
similarly to Fig. 2A in HeLa. (B) Co-precipitation of the DPT-
Vpr4 peptide with PP2A in HeLa cell extracts. Experiment was
performed similarly to Fig. 1D and the interaction with PP2A1
was analyzed by immunoblotting using antibodies against the
regulatory subunit PP2A-Ba. (C) To monitor apoptosis in Jurkat
cells treated with DPT-Vpr4 or with positive control Vpr71-96
peptides we used Annexin V (upper panel) or DiOC6 (lower panel)
assays as described in Materials and Methods. Statistical analysis
was by Anova and significance was set at P,0.05.
Found at: doi:10.1371/journal.pone.0013760.s002 (10.48 MB
TIF)
Figure S3 Co-precipitation of DPT-Vpr peptides with PP2A
subunits in cell extracts. Co-precipitation of DPT-Vpr peptides
with PP2A subunits in SK-N-SH (A) or in Jurkat (B). Immuno-
blotting was analysis was performed using antibodies against the
PP2A-Ba in SK-N-SH and PP2A catalytic subunit in HeLa cells.
Found at: doi:10.1371/journal.pone.0013760.s003 (6.02 MB TIF)
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